Human epidermal growth factor receptor 2 as a target of 1,2,3,4,6-penta- <i>O</i> -galloyl- <b>β</b> -d-glucose in colon cancer
Our findings provide a strong preclinical rationale for future clinical trials of PGG as a HER2-targeted drug in CRC and highlight its considerable potential as a novel therapeutic for CRC treatment.
Authors
- Clara Bik‐San Lau (ORCID: https://orcid.org/0000-0002-7409-1270)
- Grace Gar‐Lee Yue (ORCID: https://orcid.org/0000-0002-1726-3566)
- Chun Kwok Wong (ORCID: https://orcid.org/0000-0002-5637-8331)
- Ying‐Jun Zhang (ORCID: https://orcid.org/0000-0002-0295-337X)
- Ping-Chung Leung
- Huihai Yang (ORCID: https://orcid.org/0000-0002-9986-7362)
Institutions
- Kunming Institute of Botany (CN)
- Chinese University of Hong Kong (HK)
- Chinese Academy of Sciences (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Journal of Pharmacy and Pharmacology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1093/jpp/rgaf098
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China